Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2000 at .99 premarket?
Wook,
I went back 8 years and there has
not been this kind of volume pattern
that I can see. It must mean something.
Then again maybe not. We may never know.
Best of Luck.
Joe K.
Might be an interesting day tomorrow.
Well I guess its always interesting
in Peregrine Land.
Joe K.
It wooks for me!
Me too.
Other users are also experiencing difficulties connecting to this site, so you may have to wait a few minutes.
I looked I didn't see one.
They're in my Scottrade account today.
The reason I stayed in was the
authorized and outstanding shared
were reduced 20/1.
That told me no dilution.
That could change, but for now
I'm in.
Good luck.
Joe K.
Your picture looks spooky!!
Probably used the incorrect terminology.
Please replace with
Those trader who were inclined to
probably sold yesterday.
My apologies.
Joe K.
I think anyone who was spooked into selling,
sold yesterday. Volume isn't that low if
you multiply by 20.
It takes a while for it to show up correctly.
It probably shows the old symbol or sngx# like
my Scottrade. If you wanted to sell you'd need
to call your broker.
Joe K.
The reverse split will become effective at 9:00 AM EST on Wednesday, February 1,2012. The reverse split, which was overwhelmingly approved by the Company's stockholders on September 23, 2010 and recently unanimously authorized by its Board, will reduce the number of shares of the Company's outstanding common stock from approximately 221 million to approximately 11 million and
proportionately reduce the number of authorized shares of the Company's capital stock. The reverse split will not affect any stockholder's ownership percentage of Soligenix's shares.
Frustrated, while i believe all true longs
feel the same as you do. You seem to be
on the edge. I have a lot of this stuff
and i've gotten it all at the wrong time.
I can tell you when the stock will go down
or up by my purchases. All contrarian indicators.
If your posts read you correct, chill out.
This is not good for your mental health.
I show IBIO on hold?
I think you're confusing md's
It should be noted that the antibody Vatuximab
TM
was formerly called Bavituximab.
link didn't work for me.
Can you repost?
Who ya gonna believe.
i_like_bb_stock has 2294 followers
and has stated he's long PPHM.
Dart a billionaire has put up 2 million.
King and Thorpe who invented anti-PS.
Dr. Garnick et al.
or
a tournament backgammon player with 373 followers.
If you add up all the trades
for that second in time they
come to 100,000.
Wow
His board has 5646 followers
verses other boards that have 827.
I pick door number 1.
You must be from Tustin Ca?
Traders can ignore the Securities and Exchange Commission's new trade-through rule when executing a so-called "contingent trade."
That's the gist of a recent SEC order exempting certain qualified contingent trades from the Rule 611 trade-through provisions of the new Regulation NMS.
Contingent trades are those with two or more sides. Typically, they involve a stock and a derivative; a stock and another type of security issued by the same company; or the stocks of two different companies involved in a merger.
In other words, the successful trade of one security is contingent upon the successful trade of the other. Achieving that success can mean not altering the pricing dynamics of the marketplace.
The SEC granted the exemption on the advice of the trading committee of the Securities Industry Association. The SIA argued that contingent trades contribute to the stability of the marketplace, but would become an endangered species if traders had to comply with Rule 611 when handling them.
The SEC agreed, stating the two-part trade could become "too risky and costly to be employed successfully if they were required to meet the trade-through provisions."
Rule 611 generally prevents traders from executing their trades at prices inferior to those posted in the marketplace. They must first take out those better-priced quotes.
Doing so could change the economics of a contingent trade though. The transaction could be thrown "out of hedge" the SEC decided, making it less attractive to the broker-dealer.
Indeed, said Andy Madoff, an SIA Trading Committee member, the trade exemption was very important in protecting these kinds of trades
"Without the trade-through exemption, dealers would have been more hesitant to accept these kinds of trades," Madoff added. Trades would become too risky and costly for all concerned, he said. Customers would back off because dealers might be unable to commit capital, which would remove liquidity from the market.
Rule 611 is to go into effect in stages between February and October 2007
It amazes me that PPHM and this board
seems to tick some people off so much.
Or that they seem the overwhelming need
to save us. Just leave me alone in my
ignorance, I've played my cards, what
ever happens its my fault, and my
wife will point that out whenever
she can.
Joe K.
Must be a slow day on the biotech board.
Roth Capital likes Peregrine Pharmaceuticals Inc.'s (PPHM, $1.04, +$0.05, +5.07%) early Phase II study results for its potential hepatitis C virus treatment and anticipates a "stream of catalysts for 2012," as it reiterated its buy rating and $10 price target for the company which it called a top biotech pick.
Peregrine Provides Update on HCV Clinical Program
Preliminary Data From
Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both
Bavituximab Doses Evaluated; Supporting Further Dosing and Combination Studies;
Company to Seek Collaboration to Advance HCV Program While Continuing to Focus
on Its Lead Bavituximab Clinical Program in Multiple Solid Tumor Indications
Including Lung Cancer
TUSTIN, CA, Dec 29, 2011 (MARKETWIRE via COMTEX) -- Peregrine Pharmaceuticals,
Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing
first-in-class monoclonal antibodies for the treatment of cancer and viral
infections, today provided an update from its randomized Phase II bavituximab
study in patients infected with genotype-1 chronic hepatitis C virus (HCV).
Patients were randomized in the three-arm study to receive one of two doses of
bavituximab (0.3mg/kg or 3mg/kg) or pegylated interferon alpha-2a, in
combination with ribavirin. The goals of the study were to determine if
bavituximab plus ribavirin has a better safety profile as compared to interferon
plus ribavirin, to confirm that the combination of bavituximab and ribavirin has
antiviral activity defined as 12 week early virologic response (EVR)(1) and to
compare antiviral activity of peg-interferon plus ribavirin versus bavituximab
plus ribavirin.
A preliminary data analysis indicates that the combination of bavituximab and
ribavirin appeared safe and well tolerated with patients reporting fewer side
effects than in the interferon-containing arm. Initial data from the study also
indicated that both dose levels of bavituximab with ribavirin demonstrated
antiviral activity, however the antiviral effects in patients receiving the 0.3
mg/kg dosing level were more pronounced. A comparison of the viral data
indicated that the kinetics of antiviral activity were different between the
interferon and bavituximab treatment groups with a high percentage of those
patients achieving EVR in the interferon arm of the study doing so between week
4 and 8 and the majority of patients achieving EVR in the bavituximab groups
doing so at the week 12 end of study timepoint. More patients had achieved EVR
in the interferon-containing group by the end of the study, however based on the
nature of late EVR development in the bavituximab containing arms at the very
end of the 12 week trial, a longer-term evaluation is needed to adequately
compare the effectiveness of bavituximab and interferon. The company plans to
present full results from the study at a medical conference in 2012.
"We are pleased with the initial results we have seen from this clinical study
evaluating the combination of bavituximab with an established antiviral drug in
HCV patients. We see good evidence that the combination of bavituximab with
ribavirin has a better safety profile than an interferon containing regimen
which was one of the primary objectives of the study," said Joseph S. Shan, vice
president of clinical and regulatory affairs at Peregrine Pharmaceuticals. "In
addition, we also see that while both dose levels of bavituximab were active,
the lower dose level appears more active in HCV patients than the high dose
level. Taken together, these early results are very important in validating that
the combination of bavituximab with its immunological mechanism of action with
an active antiviral agent has a good safety profile and promising antiviral
activity. These results suggest that future studies evaluating longer
bavituximab treatment durations at or around the lower dose level in combination
with ribavirin and potentially direct acting antivirals in certain patient
populations may hold promise as interferon-free HCV therapeutic regimens."
"The early data from this trial are promising and suggest that continued
development of bavituximab in HCV patients is warranted to explore the full
immune-modulating potential of the compound in combination with antiviral
agents," said Steven W. King, president and chief executive officer of
Peregrine. "With this data in hand, we plan to actively seek development
partners interested in working with us to move the PS-targeting antiviral
program forward while we continue to focus our resources on the advancement of
our bavituximab oncology clinical program in multiple solid tumor indications
including non-small cell lung cancer (NSCLC) and pancreatic cancers as well as
other indications with high unmet medical need. With as many as six data points
coming over the next six months or so from our ongoing phase II trials in front
and second line NSCLC and the additional possible data points coming from five
additional oncology trials, this is a good time to seek partners for the
antiviral program which has shown promise in this study. We look forward to
sharing full data from the HCV trial in 2012 and to moving the program forward
in the future."
1. EVR is defined as equal or greater than a 2 log reduction in HCV RNA from
baseline.
About the Phase II HCV Trial In this multicenter Phase II randomized trial, 66
patients with previously untreated genotype-1 chronic HCV infection were
randomly assigned to one of three treatment arms. Patients received daily oral
ribavirin (1000 mg) with either weekly bavituximab (0.3 mg/kg or 3 mg/kg) or
pegylated interferon alpha-2a (180 ug) for up to 12 weeks and were tested for
safety parameters and antiviral activity.
About Bavituximab's Antiviral Approach Bavituximab is the first in a new class
of patented antibody therapeutics that target and bind to phosphatidylserine
(PS), a specific phospholipid component of cell membranes. Bavituximab helps
reactivate and direct the body's immune system to destroy infected cells and
virus particles that exhibit this specific phospholipid on their surface. Since
their target is host-derived rather than pathogen-derived, PS-targeting
antibodies have the potential for broad-spectrum antiviral activity and are also
expected to be much less susceptible to the viral mutations that often lead to
drug resistance.
About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a
biopharmaceutical company with a portfolio of innovative monoclonal antibodies
in clinical trials for the treatment of cancer and serious viral infections. The
company is pursuing multiple clinical programs in cancer and hepatitis C virus
infection with its lead product candidate bavituximab and novel brain cancer
agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities
through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com),
which provides development and biomanufacturing services for both Peregrine and
outside customers. Additional information about Peregrine can be found at
www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely
historical, including statements regarding Peregrine Pharmaceuticals'
intentions, hopes, beliefs, expectations, representations, projections, plans or
predictions of the future are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The forward-looking
statements involve risks and uncertainties including, but not limited to, the
risk that results from the randomized Phase II trial will not be consistent with
results experienced in the earlier single-arm Phase I studies, the risk that
results from the randomized Phase II trial may not support registration filings
with the U.S. Food and Drug Administration, the risk that Peregrine may not have
or raise adequate financial resources to complete the planned clinical programs,
and the risk that Peregrine will not find a development partner interested in
the antiviral applications of its PS-targeting technology. Factors that could
cause actual results to differ materially or otherwise adversely impact the
company's ability to obtain regulatory approval for its product candidates
include, but are not limited to, uncertainties associated with completing
preclinical and clinical trials for our technologies; the early stage of product
development; the significant costs to develop our products as all of our
products are currently in development, preclinical studies or clinical trials;
obtaining additional financing to support our operations and the development of
our products; obtaining regulatory approval for our technologies; anticipated
timing of regulatory filings and the potential success in gaining regulatory
approval and complying with governmental regulations applicable to our business.
Our business could be affected by a number of other factors, including the risk
factors listed from time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended April 30, 2011 and
quarterly report on Form 10-Q for the quarter ended October 31, 2011. The
company cautions investors not to place undue reliance on the forward-looking
statements contained in this press release. Peregrine Pharmaceuticals, Inc.
disclaims any obligation, and does not undertake to update or revise any
forward-looking statements in this press release.
Hmmm, very good.
I thought thats what you were pointing at.
Thanks.
TekNuLoof,
Thank you and Merry Christmas
to you and your family.
Joe K.
Google search found this.
Not much but hey its press in the NY Times.
http://topics.nytimes.com/top/news/business/companies/peregrine-pharmaceuticals-inc/index.html
I agree. Certainly does not
contribute in a constructive manner.
Scottrade shows a TradeCondition of Cancel.
TekNuLoof,
Per his IHUB description
Location Massachusetts (f.roy@verizon.net)
Inst Ownership down to 15.62%
http://www.nasdaq.com/symbol/pphm/institutional-holdings
Boris Peaker - Oppenheimer & Co. Inc., Research Division
Institutional investors moves up to 17.05%
http://www.nasdaq.com/symbol/pphm/institutional-holdings
Sheff, it's happy hour, so I can post.
I would just like to say thank you.
Joe K.
There is an $11 poison pill in place.
Pretty even handed especially for Adam.
Also, fairly long, tried to cover all the bases.
PPHM 1.30 +.30 on CNBC's ticker.
Premarket thinks so.
Stage four NSCLC, I would think so.